Clinical Trial Update: MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial results for MP-376 (Aeroquin), an inhaled levofloxacin, in patients with cystic fibrosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Aeroquin (levofloxacin for inhalation)

Snippet

Sponsor: Amgen | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-04-30